From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

FDA Launches Expanded Access Pilot ‘Project Facilitate’ - Regulatory Focus
The US Food and Drug Administration (FDA) on Monday launched a new pilot program, dubbed Project Facilitate, aimed at helping physicians complete expanded access requests for cancer patients.  
FDA, Reagan-Udall launch end-to-end expanded access program for cancer - BioCentury
FDA's Oncology Center of Excellence and the Reagan-Udall Foundation launched Expanded Access Navigator and Project Facilitate, two separate but coordinated pilot programs to provide patients and physicians with expanded ac
Enhancements to EA Navigator Improve Patient Access to Investigational Therapies
Embargoed until 9 a.m. EDT June 3, 2019 Media Inquiries: Lea Ann Browning-McNee, 301-509-1846 Consumer/Provider Inquiries: 202-849-2075
Sharpless Calls for a Nimble, Flexible, More Efficient US FDA - Pinksheet
"Sharpless said FDA's organization also must ensure collaboration across disciplines and locations, as well as with outside groups.
Sharpless Begins to Learn the Ropes While FDA Center Directors Look to the Future
Read Zach Brennan’s reference to the Foundation's Annual Public Meeting in his Regulatory Focus™ article:
Wasser Departs Reagan-Udall Foundation for the FDA
June Wasser Departs Reagan-Udall Foundation for the FDA Amar Bhat, PhD, named Interim Executive Director
Call for Nominations: Innovations in Regulatory Science Awards
Reagan-Udall Foundation for the Food and Drug Administration is seeking nominations through June 14, 2019, for its third annual Innovations in Regulatory Science Awards.
Report on Leveraging Real-World Treatment Experience from Expanded Access Protocols
Learn about strategies for Leveraging Real-World Treatment Experience from Expanded Access Protocols in the report from our November public meeting at the FDA White Oak Campus.
Updated FDA Guidance on Expanded Access
The FDA updated its guidance to clarify that listing in our Expanded Access Navigator Company Directory satisfies the 21st Century Cures Act requirement of making EA policies readily available.
CDER 2018 Drug Safety Priorities Report